Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin

Journal of Virology
Xinzhen YangJoseph Sodroski

Abstract

The envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) function as a trimer composed of three gp120 exterior glycoproteins and three gp41 transmembrane proteins. Soluble gp140 glycoproteins composed of the uncleaved ectodomains of gp120 and gp41 form unstable, heterogeneous oligomers, but soluble gp140 trimers can be stabilized by fusion with a C-terminal, trimeric GCN4 motif (X. Yang et al., J. Virol. 74:5716-5725, 2000). To understand the influence of the C-terminal trimerization domain on the properties of soluble HIV-1 envelope glycoprotein trimers, uncleaved, soluble gp140 glycoproteins were stabilized by fusion with another trimeric motif derived from T4 bacteriophage fibritin. The fibritin construct was more stable to heat and reducing conditions than the GCN4 construct. Both GCN4- and fibritin-stabilized soluble gp140 glycoproteins exhibited patterns of neutralizing and nonneutralizing antibody binding expected for the functional envelope glycoprotein spike. Of note, two potently neutralizing antibodies, immunoglobulin G1b12 and 2G12, exhibited the greatest recognition of the stabilized, soluble trimers, relative to recognition of the gp120 monomer. The observed similarities between the GCN4 and fibri...Continue Reading

References

Jun 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·E O FreedR Risser
Jan 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·P L EarlB Moss
Jul 1, 1995·The Journal of Experimental Medicine·Q J Sattentau, J P Moore
Oct 11, 1994·Proceedings of the National Academy of Sciences of the United States of America·C T WildT J Matthews
Nov 22, 1994·Proceedings of the National Academy of Sciences of the United States of America·C C BroderR W Doms
Sep 9, 1993·Nature·S JiangA R Neurath
Dec 1, 1995·Nature Structural Biology·M LuP S Kim
May 22, 1997·Nature·W WeissenhornD C Wiley
Nov 14, 1997·Proceedings of the National Academy of Sciences of the United States of America·K TanM Lu
Apr 18, 1998·Nature Structural Biology·R A FurutaC D Weiss
May 19, 1998·Nature Medicine·D R Burton, J P Moore
Sep 25, 1999·The Journal of Biological Chemistry·T MirzabekovJ Sodroski
Oct 19, 2000·The Journal of Cell Biology·R W Doms, J P Moore
Mar 7, 2001·Science·M J RootP S Kim

❮ Previous
Next ❯

Citations

Dec 16, 2004·Angewandte Chemie·Lei Wang, Peter G Schultz
Oct 6, 2006·Springer Seminars in Immunopathology·Shan Lu
Nov 8, 2003·Trends in Molecular Medicine·Ralph Pantophlet, Dennis R Burton
Aug 30, 2002·Trends in Immunology·Todd M AllenBruce D Walker
Mar 7, 2008·Proceedings of the National Academy of Sciences of the United States of America·Gary FreyBing Chen
Jul 10, 2012·Proceedings of the National Academy of Sciences of the United States of America·James M KovacsBing Chen
Nov 28, 2012·The Journal of Biological Chemistry·Guofen GaoVenigalla B Rao
Aug 4, 2010·The Journal of Experimental Medicine·John PietzschMichel C Nussenzweig
Feb 13, 2013·The Journal of Experimental Medicine·Laura E McCoy, Robin A Weiss
Jul 3, 2007·AIDS Research and Human Retroviruses·Sai Prasad N IyerWilliam C Olson
Jan 11, 2008·AIDS Research and Human Retroviruses·Lianxing LiuYiming Shao
Feb 21, 2008·AIDS Research and Human Retroviruses·Suganya SelvarajahDennis R Burton
Dec 17, 2010·AIDS Research and Human Retroviruses·Bimal K ChakrabartiRichard T Wyatt
Jan 6, 2010·Current Opinion in HIV and AIDS·Nicole A Doria-Rose, Mark Connors
Jan 10, 2012·Cold Spring Harbor Perspectives in Medicine·Peter D KwongGary J Nabel
Jul 13, 2012·Science Translational Medicine·Christopher SundlingGunilla B Karlsson Hedestam
Jul 3, 2003·Journal of Bacteriology·Peter R WeigeleJonathan King
Jul 5, 2013·Journal of Virology·Reza KhayatAndrew B Ward
Dec 31, 2010·Journal of Virology·Guiqing HuKenneth H Roux

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.